# ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment

> **NCT00322803** · PHASE2 · TERMINATED · sponsor: **elbion AG** · enrollment: 24 (—)

## Conditions studied

- Panic Disorder

## Interventions

- **DRUG:** ELB139

## Key facts

- **NCT ID:** NCT00322803
- **Lead sponsor:** elbion AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 24 (—)
- **Last updated:** 2006-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322803, "ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00322803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*